Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.

Goldstein JA.

Br J Clin Pharmacol. 2001 Oct;52(4):349-55. Review.

2.

Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype.

Herrlin K, Massele AY, Jande M, Alm C, Tybring G, Abdi YA, Wennerholm A, Johansson I, Dahl ML, Bertilsson L, Gustafsson LL.

Clin Pharmacol Ther. 1998 Oct;64(4):391-401.

PMID:
9797796
3.

[Genetic polymorphism of the CYP2C subfamily].

Chiba K.

Nihon Yakurigaku Zasshi. 1998 Jul;112(1):15-21. Review. Japanese.

PMID:
9755458
4.
5.

Biochemistry and molecular biology of the human CYP2C subfamily.

Goldstein JA, de Morais SM.

Pharmacogenetics. 1994 Dec;4(6):285-99. Review.

PMID:
7704034
6.

Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Desta Z, Zhao X, Shin JG, Flockhart DA.

Clin Pharmacokinet. 2002;41(12):913-58. Review.

PMID:
12222994
7.

Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin.

Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA.

Pharmacogenetics. 2001 Dec;11(9):803-8.

PMID:
11740344
8.

Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance.

Wang B, Wang J, Huang SQ, Su HH, Zhou SF.

Curr Drug Metab. 2009 Sep;10(7):781-834. Review.

PMID:
19925388
9.

Genetic polymorphism of S-mephenytoin 4'-hydroxylation.

Daniel HI, Edeki TI.

Psychopharmacol Bull. 1996;32(2):219-30. Review.

PMID:
8783891
10.

Polymorphisms of human cytochrome P450 2C9 and the functional relevance.

Zhou SF, Zhou ZW, Huang M.

Toxicology. 2010 Dec 5;278(2):165-88. doi: 10.1016/j.tox.2009.08.013. Epub 2009 Aug 26. Review.

PMID:
19715737
11.
12.
13.

Polymorphism of human cytochrome P450 enzymes and its clinical impact.

Zhou SF, Liu JP, Chowbay B.

Drug Metab Rev. 2009;41(2):89-295. doi: 10.1080/03602530902843483. Review.

PMID:
19514967
14.

Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs.

Hirota T, Eguchi S, Ieiri I.

Drug Metab Pharmacokinet. 2013;28(1):28-37. Epub 2012 Nov 20. Review.

15.

Differential expression and function of CYP2C isoforms in human intestine and liver.

Läpple F, von Richter O, Fromm MF, Richter T, Thon KP, Wisser H, Griese EU, Eichelbaum M, Kivistö KT.

Pharmacogenetics. 2003 Sep;13(9):565-75.

PMID:
12972955
16.

Polymorphic drug oxidation in humans.

Eichelbaum M.

Fed Proc. 1984 May 15;43(8):2298-302.

PMID:
6714436
17.

Molecular mechanisms of genetic polymorphisms of drug metabolism.

Meyer UA, Zanger UM.

Annu Rev Pharmacol Toxicol. 1997;37:269-96. Review.

PMID:
9131254
18.

Fluconazole-induced intoxication with phenytoin in a patient with ultra-high activity of CYP2C9.

Helldén A, Bergman U, Engström Hellgren K, Masquelier M, Nilsson Remahl I, Odar-Cederlöf I, Ramsjö M, Bertilsson L.

Eur J Clin Pharmacol. 2010 Aug;66(8):791-5. doi: 10.1007/s00228-010-0820-7. Epub 2010 Apr 20.

PMID:
20405111
19.

Update: genetic polymorphism of drug metabolizing enzymes in humans.

Tanaka E.

J Clin Pharm Ther. 1999 Oct;24(5):323-9. Review.

PMID:
10583694
20.

The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement.

van der Weide J, Steijns LS, van Weelden MJ, de Haan K.

Pharmacogenetics. 2001 Jun;11(4):287-91.

PMID:
11434505

Supplemental Content

Support Center